Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00216346
Other study ID # VLPM01
Secondary ID
Status Completed
Phase Phase 3
First received September 13, 2005
Last updated October 2, 2014
Start date June 2003
Est. completion date November 2004

Study information

Verified date October 2014
Source PATH
Contact n/a
Is FDA regulated No
Health authority India: Ministry of Health
Study type Interventional

Clinical Trial Summary

Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL. Paromomycin is an off-patent aminoglycoside antibiotic with anti-leishmaniasis activity. This study will test the safety and efficacy of paromomycin in the treatment of patients with VL in India.


Recruitment information / eligibility

Status Completed
Enrollment 667
Est. completion date November 2004
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 55 Years
Eligibility Inclusion Criteria:

- Age between 5-55 years (inclusive) of either gender.

- Newly diagnosed VL or VL treatment failure confirmed by spleen or bone marrow aspirate.

- Clinical signs and symptoms compatible with VL: fever of over two weeks duration and splenomegaly.

- Biochemical and haematological test values as follows:

- Haemoglobin > 5.0g/100mL

- White blood cell count > 1 x109/L

- Platelet count > 50 x 109/L

- AST, ALT and alkaline phosphatase < 3 times upper normal limit

- Prothrombin time < 5 seconds above control

- Serum creatinine levels within normal limits

- Serum potassium levels within normal limits

- HIV negative

Exclusion Criteria:

- A history of intercurrent or concurrent diseases (e.g. chronic alcohol consumption or drug addiction; renal, hepatic, cardiovascular or central nervous system disease; diabetes; tuberculosis or other infectious or major psychiatric diseases) that may introduce variables affecting the outcome of the study.

- Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up.

- An abnormal baseline audiogram (presentation with 75 dB or higher at 8KHz or below) and/or a history of significant vestibular or auditory dysfunction.

- Proteinuria (> 2+).

- A history of allergy or hypersensitivity to aminoglycosides.

- A history of major surgery within the last two weeks.

- Pregnancy or lactation. [Note: women of childbearing age must use an adequate form of contraception (documented) or agree to a period of sexual abstinence during the treatment phase of the study.]

- Previous treatment for VL within two weeks of enrolment into the study.

- Prior treatment failures with paromomycin or amphotericin B.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Paromomycin sulfate

Amphotericin B


Locations

Country Name City State
India Rajendra Memorial Research Institute of Medical Sciences (ICMR) Agam Kuan, Patna Bihar
India Kalazar Research Centre Brahmpura, Muzaffarpur Bihar
India Kalazar Research Centre Patna Bihar
India Kala-azar Medical Research Centre Rambagh Road Muzaffarpur Bihar

Sponsors (2)

Lead Sponsor Collaborator
PATH World Health Organization

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary (1) To compare the safety of injectable paromomycin to amphotericin B when administered in the proposed dosage regimens.
Primary (2) To compare the efficacy of injectable paromomycin to amphotericin B with regards to final cure rates.
Secondary - Characterization of the pharmacokinetics of injectable paromomycin in adults and children with VL
Secondary - Comparison of initial cure rates for the two regimens
Secondary - Comparison of clinical improvement rates for the two regimens
See also
  Status Clinical Trial Phase
Terminated NCT02839603 - Asymptomatic Leishmania Infection in HIV Patients
Completed NCT00370825 - Combination Chemotherapy for the Treatment of Indian Kala-Azar Phase 2
Recruiting NCT05426577 - Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Completed NCT01069198 - A Community Trial for Visceral Leishmaniasis (VL) N/A
Completed NCT01032187 - Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Phase 4
Completed NCT00371995 - Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Phase 2
Completed NCT00604955 - Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Phase 4
Completed NCT00342823 - Immunogenetics of Visceral Leishmaniasis N/A
Completed NCT04003532 - LAMP Assay for the Diagnosis of Visceral Leishmaniasis
Terminated NCT01980199 - Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Phase 2
Completed NCT00255567 - Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Phase 3
Not yet recruiting NCT06118749 - Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
Recruiting NCT04342715 - A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Completed NCT02431143 - Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Phase 2
Completed NCT01122771 - Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Phase 3
Completed NCT03636659 - Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Phase 1
Not yet recruiting NCT01566552 - Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Phase 4
Completed NCT00696969 - Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Phase 3
Completed NCT00318721 - Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar N/A
Completed NCT02011958 - Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Phase 3